Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10262808 | 0.90 | BTK (0.52) | BTK | |
| SCHEMBL10201392 | 0.90 | BTK (0.40) | BTK | |
| SCHEMBL16248124 | 0.89 | BTK (0.51) | BTK | |
| SCHEMBL17946359 | 0.88 | BTK (0.53) | BTK | |
| SCHEMBL14914745 | 0.88 | BTK (0.50) | BTK | |
| SCHEMBL10263574 | 0.87 | BTK (0.40) | BTK | |
| SCHEMBL17781610 | 0.87 | BTK (0.39) | BTK | |
| SCHEMBL8736836 | 0.86 | BTK (0.49) | BTK | |
| SCHEMBL16248113 | 0.85 | BTK (0.58) | BTK | |
| SCHEMBL12503526 | 0.84 | BTK (0.57) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280419-B1 | INDAZOLE AND AZAINDAZOLE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-3280419-B1 | INDAZOLE AND AZAINDAZOLE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| US-10246457-B2 | Indazole and azaindazole Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246457-B2 | Indazole and azaindazole Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180127411-A1 | INDAZOLE AND AZAINDAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127411-A1 | INDAZOLE AND AZAINDAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127411-A1 | INDAZOLE AND AZAINDAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-10 | — | — | US | disclosed |
| EP-3280419-A1 | INDAZOLE AND AZAINDAZOLE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | disclosed |
| EP-2403846-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2016-11-02 | — | — | EP | disclosed |
| EP-2403846-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2016-11-02 | — | — | EP | disclosed |
| WO-2012020008-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012020008-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2403846-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010100070-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010100070-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN | 2010-09-02 | — | — | US | disclosed |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN | 2010-09-02 | — | — | US | disclosed |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127411-A1 | INDAZOLE AND AZAINDAZOLE BTK INHIBITORS | BTK, SYK, ABL1 | BTK 1/4885 |
| US-10246457-B2 | Indazole and azaindazole Btk inhibitors | BTK, SYK, ABL1 | BTK 1/4885 |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | BTK 1/4885 |
| US-20100222325-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.